Money Genius Group
  • Investing
  • World News
  • Stock
  • Tech News
Investing

Successful Completion of Placement to Accelerate Clinical Programs

by March 4, 2025
March 4, 2025

Invion Limited (ASX: IVX) (“Invion” or the “Company”) is pleased to announce that it has successfully completed a new share placement (Placement) to raise $2.0 million to advance research and development in Photosoft as a potential treatment for a range of cancers.

Highlights:

Invion raises $2M via a share placement with the new shares priced at $0.14, a 2.5% premium to the 30-day VWAP and nil discount to last closing price
Investors in the placement will also receive one unquoted three-year option (exercise price of $0.28) for every new share
Proceeds from the placement will be used to:

Recruit from a second site for Invion’s Phase I/II skin cancer trial
Initiate a Phase I/II anogenital trial with the Peter MacCallum Cancer Centre
Fund general working capital

A successful outcome in the anogenital trial may enable orphan drug designation in the US to fast-track trials in the rare disease indication(s)
Multiple milestones on the horizon, including:

Results from the skin cancer trial
Initiation & progress on the anogenital trial
Updates on the glioblastoma, oesophageal cancer and HPV studies that are fully funded by Invion’s partners

The offer price for the new shares of $0.14 per share represents a 2.5% premium to the 30-day volume-weighted average price (VWAP) and a zero discount to its last closing price before the Placement announcement on 27 February 2025.

The lead manager for the Placement, Blue Ocean Equities (Lead Manager), received strong demand for the Placement, which was originally seeking to raise $1.5 million from sophisticated investors.

The Placement will comprise of two tranches:

Tranche 2: Placement of the balance of shares, conditional on the Company obtaining shareholder approval at the Extraordinary General Meeting (EGM) expected to be held in April 2025.

Investors in the placement will receive one unquoted attaching option for each new share with an exercise price of $0.28 and will expire three years from issue, subject to shareholder approval at the EGM.

The Lead Manager is to receive a capital raising fee of 6% on the proceeds of the Placement and will also receive a tranche of options to an equivalent value of approximately $80,000 using a Black Scholes options pricing formula with the following inputs:

Exercise price – each option will have an exercise price which is a 50% premium to the 15-day VWAP calculation as at the date of the placement.
Expiry – the options will expire 2 years from the date of issuance.
Volatility rate – 100%.
Risk Free Rate – 5%.

The Company will lodge an appendix 3B with the ASX with these details as soon as the number of options has been calculated. These issue of these options is subject to the approval of shareholders at the EGM.

Use of Proceeds from the Placement

Proceeds from the raise will be used to recruit from a second clinical site for Invion’s Phase I/II non-melanoma skin cancer (NMSC) trial, initiate a Phase I/II anogenital trial with the Peter MacCallum Cancer Centre (Peter Mac) and for general working capital.

Invion plans to leverage the safety data from the NMSC trial to accelerate a pathway to the anogenital trial as both trials are using the same topical formulation of INV043. Anogenital cancers include penile, vulva and anal cancers, which are rare diseases.

A successful outcome in the anogenital trial may enable orphan drug designation with the U.S. Food & Drug Administration (FDA). The granting of an orphan drug designation will give Invion a faster and more cost-effective path to commercialise Photosoft for the treatment of the rare disease(s) in question.

Thian Chew, Invion’s Executive Chair and CEO, commented:

“We are delighted to welcome new shareholders to Invion via the Placement, many of whom are sophisticated investors in the biotech space that are supporting the Company after reviewing our achievements and the multiple milestones in our horizon.

“In addition to the skin and anogenital cancer trials, these milestones also include updates on the glioblastoma, oesophageal cancer and human papilloma virus studies that are fully funded by our partners.”

This announcement was approved for release by Invion’s Board of Directors.

Click here for the full ASX Release

This post appeared first on investingnews.com
previous post
High Resolution Ground Magnetics Commences at 100% – Owned Kiabye Gold Project, Western Australia

You may also like

Cardiol Therapeutics to Present at TD Cowen 45th...

March 3, 2025

Nuclear Fuels Acquires TenSleep Uranium Project with Athabasca...

March 3, 2025

StrategX Discovers Extensive High-Grade Graphite at Nagvaak and...

March 3, 2025

Awalé Hits 1.4 g/t Gold Eq. over 60...

March 3, 2025

Falco Receives Additional Comments and Questions From the Ministry...

March 3, 2025

High Resolution Ground Magnetics Commences at 100% –...

March 4, 2025

Strategic Business Review Update

March 4, 2025

Strong continuity of high-grade gold in Sandstone drilling

March 4, 2025

Electric Royalties: Royalty Company Focused on Clean Energy...

March 3, 2025

RETRANSMISSION: LaFleur Minerals to Restart Gold Milling at...

March 3, 2025

Cardiol Therapeutics to Present at TD Cowen 45th...

March 3, 2025

Nuclear Fuels Acquires TenSleep Uranium Project with Athabasca...

March 3, 2025

StrategX Discovers Extensive High-Grade Graphite at Nagvaak and...

March 3, 2025

Awalé Hits 1.4 g/t Gold Eq. over 60...

March 3, 2025

Falco Receives Additional Comments and Questions From the Ministry...

March 3, 2025

High Resolution Ground Magnetics Commences at 100% –...

March 4, 2025

Strategic Business Review Update

March 4, 2025

Strong continuity of high-grade gold in Sandstone drilling

March 4, 2025

Electric Royalties: Royalty Company Focused on Clean Energy...

March 3, 2025

RETRANSMISSION: LaFleur Minerals to Restart Gold Milling at...

March 3, 2025

    Sign up for our newsletter to receive the latest insights, updates, and exclusive content straight to your inbox! Whether it's industry news, expert advice, or inspiring stories, we bring you valuable information that you won't find anywhere else. Stay connected with us!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • DP Trading Room: Bitcoin Surges!

      March 4, 2025
    • The Best Five Sectors, #9

      March 4, 2025
    • Financials’ Strong Week Lifts Them to Within a Whisker of an All-Time High

      March 3, 2025
    • Growth Stocks Tumbling; Where to Find Safe Havens Now!

      March 1, 2025
    • 3 Compelling Charts in the Financial Sector

      March 1, 2025
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 moneygeniusgroup.com | All Rights Reserved

    Money Genius Group
    • Investing
    • World News
    • Stock
    • Tech News